Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 3:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–42 of 42 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Refresh Plus Clear all
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival

NCT01072357
View directory record Official record
Conditions
Corneal Neovascularization, Corneal Graft Failure
Interventions
Avastin® (bevacizumab), 0.9% NaCl & Refresh Liquigel
Drug
Lead sponsor
Reza Dana, MD
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 15, 2018 · Synced Oct 22, 2026, 3:56 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Compare a New Eye Drop Formulation With Refresh Contacts®

NCT01844388
View directory record Official record
Conditions
Contact Lens Lubrication
Interventions
carboxymethylcellulose based eye drop formula, carboxymethylcellulose sodium based eye drop solution
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
365 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Bloomington, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 22, 2026, 3:56 PM EDT
Terminated Not applicable Interventional Results available

CytoSorb® Reduction of FREee Hemoglobin/Acute Kidney Injury (AKI) During Cardiac Surgery

NCT03384875
View directory record Official record
Conditions
Elective Cardiac Surgery
Interventions
CytoSorb
Device
Lead sponsor
CytoSorbents, Inc
Industry
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
20
States / cities
New Haven, Connecticut • Chicago, Illinois • Indianapolis, Indiana + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Oct 22, 2026, 3:56 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Tear Lipid Layer Thickness With Emollient Eye Drops

NCT03380624
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Refresh Optive, Refresh Optive MEGA-3
Drug
Lead sponsor
Ohio State University
Other
Eligibility
30 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 22, 2026, 3:56 PM EDT
Completed Phase 4 Interventional

Efficacy of Cyclosporine for the Prevention and Treatment of Dry Eye Symptoms Following LASIK or Photorefractive Keratectomy

NCT00349440
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Cyclosporine, Refresh Plus
Drug
Lead sponsor
Innovative Medical
Industry
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Greensboro, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 26, 2008 · Synced Oct 22, 2026, 3:56 PM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study of a New Eye Drop Formulation in Patients With Dry Eye Disease.

NCT02553772
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Carboxymethylcellulose Based Eye Drop, Carboxymethylcellulose Sodium 0.5%
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
10
States / cities
Azusa, California • Burbank, California • Glendale, California + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 22, 2026, 3:56 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Multi-Center Study of the Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival

NCT01996826
View directory record Official record
Conditions
Corneal Neovascularization, Corneal Graft Failure
Interventions
Avastin® (bevacizumab), 0.9% NaCl & Refresh Liquigel
Drug
Lead sponsor
Reza Dana, MD
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
3
States / cities
Miami, Florida • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Oct 22, 2026, 3:56 PM EDT
Terminated Not applicable Interventional Results available

The Effects of Cyclosporin A in a Low Humidity Environment, on the Ocular Surface

NCT02199964
View directory record Official record
Conditions
Dry Eye
Interventions
Cyclosporin 0.05% emulsion, Endura, Refresh artificial tears
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 20, 2020 · Synced Oct 22, 2026, 3:56 PM EDT
Completed Not applicable Interventional Results available

Safety and Efficacy of an Artificial Tear for the Treatment of Dry Eye

NCT00514852
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
Carboxymethylcellulose and Glycerin based artificial tear, Carboxymethylcellulose
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 15, 2009 · Synced Oct 22, 2026, 3:56 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Brimonidine Eye Drops for Treatment of Ocular Graft-vs-Host Disease (oGVHD)

NCT02975557
View directory record Official record
Conditions
Dry Eye, Ocular Graft vs Host Disease, Meibomian Gland Dysfunction
Interventions
Brimonidine 0.15%, Brimonidine 0.075%, Placebo
Drug
Lead sponsor
Sandeep Jain, MD
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 8, 2019 · Synced Oct 22, 2026, 3:56 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Health-Kit Enabled Mobile App for Tobacco Cessation

NCT06292130
View directory record Official record
Conditions
Cigarette Smoking
Interventions
refresh
Behavioral
Lead sponsor
Pro-Change Behavior Systems
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
South Kingstown, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 22, 2026, 3:56 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Carboxymethylcellulose Artificial Tears on the Eye Microbiome

NCT05292755
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Carboxymethylcellulose (CMC) Artificial Tears, Preservative-free, CMC-free Artificial Tears (control)
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 20, 2023 · Synced Oct 22, 2026, 3:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Evaluate The Safety, Tolerability And Pk Of Pazopanib Eye Drops In Healthy Adult And Elderly Subjects.

NCT00463320
View directory record Official record
Conditions
Macular Degeneration, Age-related Macular Degeneration
Interventions
Pazopanib eye drops and Allergen Refresh Plus eye drops
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years to 55 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
2
States / cities
Fargo, North Dakota • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 19, 2012 · Synced Oct 22, 2026, 3:56 PM EDT
Completed Not applicable Interventional Results available

Efficacy of Virtual Reality Exposure Therapy Scripts for Social Phobia

NCT04850989
View directory record Official record
Conditions
Social Anxiety Disorder
Interventions
Pico Goblin VR headset
Device
Lead sponsor
Penn State University
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 22, 2026, 3:56 PM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Sustainability Via Active Garden Education Wellness Implementation Strategies in Early Care and Education

NCT07228819
View directory record Official record
Conditions
Implementation Science, Diet, Food, and Nutrition, Child Care, Motor Behavior
Interventions
SAGE Basic, SAGE e-support, SAGE in-person support, Learning collaborative
Behavioral
Lead sponsor
Arizona State University
Other
Eligibility
3 Years and older
Enrollment
871 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Oct 22, 2026, 3:56 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Tear Osmolarity Over Time With Artificial Tears

NCT01227226
View directory record Official record
Conditions
Dry Eye
Interventions
Artificial tears
Drug
Lead sponsor
Hom, Milton M., OD, FAAO
Individual
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Azusa, California
Source: ClinicalTrials.gov public record
Updated Feb 7, 2011 · Synced Oct 22, 2026, 3:56 PM EDT
Terminated Phase 3 Interventional

Randomized Study of Extended Treatment With Firibastat in Treatment-Resistant Hypertension (REFRESH)

NCT04857840
View directory record Official record
Conditions
Hypertension (HTN)
Interventions
Firibastat (QGC001) Period 1
Drug
Lead sponsor
Quantum Genomics SA
Industry
Eligibility
18 Years to 99 Years
Enrollment
419 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Manassas, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 17, 2023 · Synced Oct 22, 2026, 3:56 PM EDT
Completed Not applicable Interventional Results available

Virtual Reality for Pain Management in Orthopaedic Patients

NCT04152447
View directory record Official record
Conditions
Pain, Musculoskeletal
Interventions
VR device
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 15, 2022 · Synced Oct 22, 2026, 3:56 PM EDT